Skip to content

A prospective randomized controlled trial of terlipressin in reducing bleeding during hepatectomy

A prospective randomized controlled trial of terlipressin in reducing bleeding during hepatectomy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039142
Enrollment
Unknown
Registered
2020-10-19
Start date
2020-11-01
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatectomy

Interventions

Group G:Terlipressin was infused continuously during the operation
Group T:Nitroglycerin was used at the beginning of operation to achieve the goal of controlled low central venous pressure

Sponsors

Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged from 18 to 65 years old, regardless of gender; 2. ASA I - II, cardiac function grade 1; 3. The patients who were diagnosed as primary liver cancer before operation were confirmed as hepatocellular carcinoma, cholangiocarcinoma or mixed cell carcinoma by postoperative pathology; 4. Patients undergoing elective partial hepatectomy (residual liver volume > 40%); 5. The liver function was child Pugh grade: Grade A, or grade B was improved to grade A by preoperative treatment; 6. Patients with normal renal function before operation.

Exclusion criteria

Exclusion criteria: 1. Patients with grade 3 or above hypertension or uncontrolled grade 1-2 hypertension (daily blood pressure > 140 / 90mmHg after taking antihypertensive drugs); 2. Patients with cardiovascular and cerebrovascular diseases (coronary heart disease, cerebral infarction, etc.); 3. Patients with BMI > 30kg / m2; 4. Patients with known allergy to terlipressin or nitroglycerin; 5. Patients with active hepatitis; 6. Patients with liver cancer complicated with large vessel invasion, recurrence of liver cancer and reoperation; 7. Patients with active gastrointestinal bleeding, liver dysfunction, severe and uncorrectable coagulation dysfunction, or other contraindications of terlipressin.

Design outcomes

Primary

MeasureTime frame
blood loss;

Secondary

MeasureTime frame
Drainage volume of postoperative ascites;Urine output;

Countries

China

Contacts

Public ContactHuang Xiongqing

Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University

1259302471@qq.com+86 18922711399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026